To determine the impact of latent tuberculosis on severity and outcomes in patients with suspected SARS-COV-19 infectio
Not Applicable
- Conditions
- Health Condition 1: A00-B99- Certain infectious and parasitic diseasesHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/11/029203
- Lead Sponsor
- AIIMS Research Section
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Consecutively admitted COVID positive patients
Exclusion Criteria
Refusal of consent
Active tuberculosis
HIV
Post 72 hours of admission or more than 7 days of symptom onset
Any known immunodeficiency
Pregnancy
Malignancy
Any other known systemic infection or disease altering T cell pathway
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine prevalence of latent tuberculosis with respect to severity of illness amongst suspected SARS-COV-19 patientsTimepoint: At enrollment
- Secondary Outcome Measures
Name Time Method Co-relation between LTBI and various routine laboratory investigations done routinely as per hospital protocol (differential and absolute lymphocyte counts, monocyte counts, fibrinogen, D-dimer, ferritin)Timepoint: Till discharge from hospital, or death (whichever is earlier)